BIOMAT Database Logo BIOMAT Database Logo

High-dose melphalan for multiple myeloma. 1983

M Cavo, and M Baccarani, and M Gobbi, and S Tura

UI MeSH Term Description Entries
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Cavo, and M Baccarani, and M Gobbi, and S Tura
High-risk multiple myeloma treated with high-dose melphalan.
January 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M Cavo, and M Baccarani, and M Gobbi, and S Tura
[High-dose melphalan in patients with multiple myeloma].
March 1999, Bulletin du cancer,
M Cavo, and M Baccarani, and M Gobbi, and S Tura
Outpatient high-dose melphalan in multiple myeloma patients.
January 2007, Transfusion,
M Cavo, and M Baccarani, and M Gobbi, and S Tura
Multiple myeloma treated with high dose intravenous melphalan.
May 1987, British journal of haematology,
M Cavo, and M Baccarani, and M Gobbi, and S Tura
Prognostic factors with high-dose melphalan for refractory multiple myeloma.
December 1988, Blood,
M Cavo, and M Baccarani, and M Gobbi, and S Tura
Primary refractory multiple myeloma - what role for high dose melphalan?
December 2020, Leukemia & lymphoma,
M Cavo, and M Baccarani, and M Gobbi, and S Tura
Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma.
April 1983, European journal of cancer & clinical oncology,
M Cavo, and M Baccarani, and M Gobbi, and S Tura
Oral complications of high-dose melphalan in multiple myeloma.
August 1987, Oral surgery, oral medicine, and oral pathology,
M Cavo, and M Baccarani, and M Gobbi, and S Tura
Multiple myeloma--complete remission with high dose melphalan chemotherapy.
January 1985, Cancer investigation,
M Cavo, and M Baccarani, and M Gobbi, and S Tura
Severe gastrointestinal mucositis following high dose melphalan therapy for multiple myeloma.
February 2013, World journal of gastroenterology,
Copied contents to your clipboard!